Loading clinical trials...
Loading clinical trials...
PROPHETIC - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatment. Blood samples are collected prior to and during the treatment period and analyzed as part of the ongoing development of thealgorithm.
The goal of this research study is to develop an algorithm that predicts the patient's treatment outcome.This algorithm will serve as a tool for physicians when making treatment decisions, specifically for stage IV NSCLC and malignant melanoma patients receiving anti-cancer treatments. The investigators also aim to identify the metabolic pathways that could lead to better therapeutic options. The patients will be given their treatment according to the institute's standard of care. The patients will provide two blood samples and clinical data will be collected from their medical records. In the first part of the trial, the data obtained from the blood samples and the medical records of the patients will be used to develop the prediction algorithm, and in the second part of the trial, the algorithm will be validated by comparing the objective response rate of the patients to the theoretical response prediction of the algorithm.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Birmingham VAHCS
Birmingham, Alabama, United States
Mayo Clinic
Jacksonville, Florida, United States
University of Miami
Miami, Florida, United States
Florida Cancer Specialist and Research Institute
Orlando, Florida, United States
Protean Biodiagnosics
Orlando, Florida, United States
Northwest Community Healthcare
Rolling Meadows, Illinois, United States
Helen Nassif Community Cancer Center
Cedar Rapids, Iowa, United States
Rutgers Cancer Institute
New Brunswick, New Jersey, United States
Roswell Park
Buffalo, New York, United States
West Clinic
Germantown, Tennessee, United States
Start Date
October 1, 2019
Primary Completion Date
October 1, 2029
Completion Date
October 1, 2029
Last Updated
October 15, 2025
10,000
ESTIMATED participants
Plasma sample collection
OTHER
Lead Sponsor
OncoHost Ltd.
NCT03223155
NCT02495896
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05566223